Dana Weeks
About Dana Weeks
Dana Weeks (age 54) is an independent Class I director of Blue Owl Capital Inc. (OWL) serving since May 2021; she is CEO and Co‑Founder of MedTrans Go, a healthcare technology start‑up, and holds a BA with Honors from Stanford University and an MBA from Columbia Business School . She sits on OWL’s Audit Committee and has prior roles at AT&T, Pfizer, and entrepreneurial ventures; she co‑founded the Black Angel Tech Foundation and served as its President from April 2016 to September 2019 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Black Angel Tech Foundation | Co‑Founder; President | Apr 2016 – Sep 2019 | Foundation created to support/increase underrepresented minorities in technology |
| AT&T | Various positions | Not disclosed | Corporate operating experience |
| Pfizer | Various positions | Not disclosed | Corporate operating experience |
| Entrepreneurial ventures | Various roles | Not disclosed | Innovation-focused roles |
External Roles
| Organization | Role | Tenure |
|---|---|---|
| MedTrans Go (Atlanta) | Chief Executive Officer; Co‑Founder | Current |
| The Westminster Schools of Atlanta | Board of Trustees | Current |
| Jack & Jill (Atlanta Chapter) | Treasurer | Current |
| Stride: Win Your Way | Advisory Board Member | Current |
| Wellstar Hospital Foundation | Board Member | Current |
| Access Foundation | Board Member | Current |
| Stanford LEAD Council | Co‑Chair | Current |
| Stanford Humanities & Sciences Council | Member | Current |
| Stanford Athletics Board | Member | Current |
| Columbia Business School Women’s Circle | Founding Member | Current |
Board Governance
- Structure: OWL maintains a classified board; Weeks is a Class I director nominated for a term expiring at the 2028 Annual Meeting .
- Independence: Board determined Weeks is independent under NYSE listing standards .
- Committees: Member of Audit Committee; Audit Committee members are independent; chair is Claudia Holz .
- Attendance and engagement: In 2024, the Board held 9 meetings and the Audit Committee held 10; each director attended at least 75% of meetings of the Board and committees on which they served; all directors then serving attended the 2024 Annual Meeting .
- Executive sessions: Independent directors meet without management in regularly scheduled sessions .
- Controlled company status: OWL qualifies for the NYSE controlled company exemption and does not have a nominating or compensation committee comprised solely of independent directors; certain compensation functions are handled by senior management .
| Item | Detail | Source |
|---|---|---|
| Committee | Audit Committee – Member | |
| Committee Chair Roles | None disclosed for Weeks | |
| Independence | Independent director | |
| Board Meetings (2024) | 9; ≥75% attendance by each director | |
| Audit Meetings (2024) | 10; ≥75% attendance by each member | |
| Executive Sessions | Independent director sessions without management |
Fixed Compensation
- Program structure for independent directors (2024): Cash retainer $150,000; Audit Committee member fee $25,000 (chair $50,000); annual RSU grant increased in FY2024 from $100,000 to $200,000; RSUs vest fully in the year following grant .
- 2024 actual for Weeks: Cash fees $175,000; Stock awards grant date fair value $192,809; total $367,809. RSU grant of 10,887 units on May 9, 2024, vesting May 15, 2025 .
| Component | 2024 Amount | Notes |
|---|---|---|
| Annual cash retainer | $150,000 | Independent director program |
| Audit Committee member fee | $25,000 | Member (non‑chair) |
| RSU annual grant (program level) | $200,000 | Increased as of Apr 23, 2024; vests following year |
| Fees earned (Weeks) | $175,000 | 2024 actual |
| Stock awards (Weeks) | $192,809 | Grant date fair value under ASC 718 |
| RSU units (Weeks) | 10,887 | Granted May 9, 2024; vests May 15, 2025 |
| Total (Weeks) | $367,809 | 2024 total |
Performance Compensation
- No performance‑conditioned director compensation disclosed; director equity grants are time‑based RSUs, and OWL does not currently grant stock options or similar option‑like instruments (Item 402(x)(1)) .
Other Directorships & Interlocks
| Category | Detail |
|---|---|
| Other public company boards | None disclosed in OWL’s proxy biography for Weeks |
| Audit committee limits | OWL discourages Audit Committee members from serving on >2 additional public company audit committees; no other audit committee memberships disclosed for Weeks |
| Interlocks/related parties | No Weeks-specific related-party transactions disclosed in “Certain Relationships and Related Transactions” section – |
Expertise & Qualifications
- Education: BA with Honors, Stanford University; MBA, Columbia Business School .
- Industry/functional expertise: Healthcare technology CEO; prior corporate roles at AT&T and Pfizer; founder/leader in minority tech initiatives; active governance roles across academic and nonprofit boards .
- Board qualification: Audit Committee member; audit committee financial expert designation is held by Claudia Holz (not Weeks) .
Equity Ownership
| Metric | Amount | Notes |
|---|---|---|
| Class A Shares beneficially owned | 38,575 | Includes 10,887 RSUs vesting May 15, 2025 and 27,688 shares held directly |
| Direct Class A holdings | 27,688 | Direct ownership |
| Unvested RSUs | 10,887 | Grant 5/9/2024; vests 5/15/2025 |
| Ownership as % of Class A outstanding | ~0.006% | 38,575 / 625,652,391 Class A shares outstanding as of 4/17/2025 |
| Pledging/Hedging | No pledges disclosed for Weeks; firm prohibits hedging/short‑selling; pledging only by approval under strict policy |
Governance Assessment
-
Positive signals:
- Independent director on Audit Committee; independent committee composition; regular executive sessions enhance oversight .
- Engagement: ≥75% attendance and presence at 2024 Annual Meeting indicates acceptable participation .
- Alignment: Annual RSU grant increased to $200,000 in 2024 with time‑based vesting; Weeks holds 38,575 Class A shares including RSUs, with no pledges disclosed .
-
Areas to monitor / potential red flags:
- Controlled company exemption: OWL is a controlled company (Principals hold 80% voting power), and does not maintain independent‑only nominating or compensation committees; compensation decisions largely handled by management, which can weaken independent oversight levers .
- Ownership concentration: Weeks’ direct and RSU holdings are a very small fraction (~0.006%) of Class A shares outstanding, limiting “skin‑in‑the‑game” leverage relative to super‑voting classes and insiders .
- External commitments: CEO role at MedTrans Go plus numerous external boards/advisory roles; while OWL has no formal limits on outside boards (other than audit committee guidance), investors may monitor time allocation and potential conflicts; no related‑party transactions involving Weeks are disclosed –.
-
Policy protections:
- Insider Trading and Hedging Policy: Prohibits hedging, short‑selling, derivative speculation without approval; pledging permitted only under stringent audit committee‑approved conditions .
- Clawback Policy: Complies with NYSE Section 303A.14; recovery of excess incentive‑based compensation upon restatement; no recoveries noted to date .